Stocktoria
VYNE Therapeutics Inc. VYNE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-01-25
VYNE Therapeutics Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -5219.1% | -8710.0% | -6900.5% | -7189.7% | -4179.5% |
| Net margin | -4646.1% | -7950.9% | -6710.4% | -4865.8% | -7876.4% |
| FCF margin | — | — | — | — | -6054.5% |
| Return on assets | -87.8% | -59.5% | -29.1% | -56.9% | -109.4% |
| Return on equity | -95.4% | -76.5% | -32.1% | -74.4% | -150.8% |
| Debt / equity | 0.00× | 0.00× | 0.00× | 0.00× | 0.00× |
| Current ratio | 12.53 | 4.35 | 12.73 | 4.10 | 3.43 |
| Revenue growth | 13.8% | 18.2% | -11.1% | -48.8% | -95.6% |
Source: SEC EDGAR filings · CIK 0001566044 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.